Rituximab: Difference between revisions
Jump to navigation
Jump to search
imported>Howard C. Berkowitz No edit summary |
mNo edit summary |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
In [[medicine]], [[rituximab]] is a [[medication]] that is "a genetically engineered anti-CD20 | In [[medicine]], [[rituximab]] is a [[medication]] that is "a genetically engineered anti-[[CD20 antigen|CD20]] [[antibody]] for the treatment of B-cell [[lymphoma]]."<ref>{{MeSH}}</ref> | ||
==References== | ==References== | ||
{{reflist}} | |||
==External links== | ==External links== | ||
{{CZMed}} | {{CZMed}}[[Category:Suggestion Bot Tag]] | ||
Latest revision as of 11:01, 12 October 2024
In medicine, rituximab is a medication that is "a genetically engineered anti-CD20 antibody for the treatment of B-cell lymphoma."[1]
References
- ↑ Anonymous (2024), Rituximab (English). Medical Subject Headings. U.S. National Library of Medicine.
External links
The most up-to-date information about Rituximab and other drugs can be found at the following sites.
- Rituximab - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Rituximab - Drug information for consumers from MedlinePlus (U.S. National Library of Medicine).
- Rituximab - Detailed information from DrugBank.